Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2-Reference-Cited by-同舟云学术

Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2

Published:2003-12 Issue:4 Volume:312 Page:1236-1243
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Gavrieli Maya,Watanabe Norihiko,Loftin Susan K,Murphy Theresa L,Murphy Kenneth M

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference39 articles.

1. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

2. Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation

3. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance

4. Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) Engagement Delivers an Inhibitory Signal through the Membrane-Proximal Region in the Absence of the Tyrosine Motif in the Cytoplasmic Tail

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The BTLA–HVEM axis restricts CAR T cell efficacy in cancer;Nature Immunology;2024-06

2. Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies;Journal of Experimental & Clinical Cancer Research;2024-05-31

3. THEMIS promotes T cell development and maintenance by rising the signaling threshold of the inhibitory receptor BTLA;Proceedings of the National Academy of Sciences;2024-05-07

4. Discovery of a novel SHP2 allosteric inhibitor using virtual screening, FMO calculation, and molecular dynamic simulation;Journal of Molecular Modeling;2024-04-13

5. Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?;Frontiers in Immunology;2024-03-05